By Jason Derry --
Dyax Corp. and the Australian national scientific
research agency, CSIRO, have announced a collaborative partnership to discover and develop antibodies for treating
cancer. Dyax will provide
the antibody libraries and screen for potential clinical leads, while CSIRO will test the leads and work on developing the leads into
clinically useful therapeutics. According to its website, Dyax's mission is to generate biotherapeutics,
particularly in the area of immunology and oncology. In addition, Dyax has entered over 70
revenue-generating collaborative and licensing arrangements involving
discovery, affinity separation, diagnostic imaging, and research reagents.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments